Isolated central nervous system progression on Crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation?
- PMID: 22986231
- PMCID: PMC3542227
- DOI: 10.4161/cbt.22255
Isolated central nervous system progression on Crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation?
Abstract
Advanced non-small lung cancer (NSCLC) remains almost uniformly lethal with marginal long-term survival despite efforts to target specific oncogenic addiction pathways that may drive these tumors with small molecularly targeted agents and biologics. The EML4-ALK fusion gene encodes a chimeric tyrosine kinase that activates the Ras signaling pathway, and this fusion protein is found in approximately 5% of NSCLC. Targeting EML4-ALK with Crizotinib in this subset of NSCLC has documented therapeutic efficacy, but the vast majority of patients eventually develop recurrent disease that is often refractory to further treatments. We present the clinicopathologic features of three patients with metastatic NSCLC harboring the EML4-ALK translocation that developed isolated central nervous system (CNS) metastases in the presence of good disease control elsewhere in the body. These cases suggest a differential response of NSCLC to Crizotinib in the brain in comparison to other sites of disease, and are consistent with a previous report of poor CNS penetration of Crizotinib. Results of ongoing clinical trials will clarify whether the CNS is a major sanctuary site for EML4-ALK positive NSCLC being treated with Crizotinib. While understanding molecular mechanisms of resistance is critical to overcome therapeutic resistance, understanding physiologic mechanisms of resistance through analyzing anatomic patterns of failure may be equally crucial to improve long-term survival for patients with EML4-ALK translocation positive NSCLC.
Figures
![None](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3542227/bin/cbt-13-1376-g1.gif)
![None](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3542227/bin/cbt-13-1376-g2.gif)
![None](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3542227/bin/cbt-13-1376-g3.gif)
![None](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3542227/bin/cbt-13-1376-g4.gif)
![None](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3542227/bin/cbt-13-1376-g5.gif)
Similar articles
-
Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer.Ann Oncol. 2017 Apr 1;28(4):791-797. doi: 10.1093/annonc/mdw693. Ann Oncol. 2017. PMID: 28039177
-
The biology and clinical features of non-small cell lung cancers with EML4-ALK translocation.Curr Oncol Rep. 2012 Apr;14(2):105-10. doi: 10.1007/s11912-012-0213-4. Curr Oncol Rep. 2012. PMID: 22311682 Review.
-
ALK inhibitors in the treatment of advanced NSCLC.Cancer Treat Rev. 2014 Mar;40(2):300-6. doi: 10.1016/j.ctrv.2013.07.002. Epub 2013 Aug 7. Cancer Treat Rev. 2014. PMID: 23931927 Review.
-
Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer.Oncotarget. 2016 Jan 5;7(1):1066-75. doi: 10.18632/oncotarget.6279. Oncotarget. 2016. PMID: 26544515 Free PMC article.
-
Long-lasting response to crizotinib in brain metastases due to EML4-ALK-rearranged non-small-cell lung cancer.BMJ Case Rep. 2013 Sep 10;2013:bcr2013200867. doi: 10.1136/bcr-2013-200867. BMJ Case Rep. 2013. PMID: 24022905 Free PMC article.
Cited by
-
Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study).Target Oncol. 2023 Nov;18(6):905-914. doi: 10.1007/s11523-023-01014-z. Epub 2023 Nov 15. Target Oncol. 2023. PMID: 37966566
-
Inhibition of Anaplastic Lymphoma Kinase (Alk) as Therapeutic Target to Improve Brain Function in Neurofibromatosis Type 1 (Nf1).Cancers (Basel). 2023 Sep 15;15(18):4579. doi: 10.3390/cancers15184579. Cancers (Basel). 2023. PMID: 37760547 Free PMC article. Review.
-
WBRT for brain metastases from non-small cell lung cancer: for whom and when?-Contemporary point of view.J Thorac Dis. 2021 May;13(5):3246-3257. doi: 10.21037/jtd-2019-rbmlc-06. J Thorac Dis. 2021. PMID: 34164217 Free PMC article. Review.
-
Central nervous system relapse in a child with anaplastic large cell lymphoma: potential for new therapeutic strategies.Cancer Rep (Hoboken). 2021 Oct;4(5):e1377. doi: 10.1002/cnr2.1377. Epub 2021 Apr 6. Cancer Rep (Hoboken). 2021. PMID: 33822480 Free PMC article.
-
Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong.Cost Eff Resour Alloc. 2020 Nov 7;18(1):50. doi: 10.1186/s12962-020-00244-6. Cost Eff Resour Alloc. 2020. PMID: 33292314 Free PMC article.
References
-
- Shaw AT, Solomon B, Kenudson MM. Crizotinib and testing for ALK. J Natl Compr Canc Netw. 2011;9:1335–41. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical